Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825631 | Clinical Therapeutics | 2013 | 22 Pages |
Abstract
In healthy volunteers, DR-DMF was well tolerated over 4 days of dosing, with a PK profile consistent with that previously reported and no evidence of accumulation. Aspirin pretreatment reduced the incidence and intensity of flushing without affecting GI events or the DR-DMF PK profile. Elevated levels of PGD2 in some DR-DMF-treated individuals suggest that flushing may be, at least in part, prostaglandin mediated. ClinicalTrials.gov identifier: ID: NCT01281111.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Sarah I. MD, MRCP, MSc, Ivan PhD, Heidy PhD, John PhD, Ron PhD, Ginger L. PhD, Robert H. PhD, Mark MD, Katherine T. MD,